PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating ...
MANCHESTER — Mavacamten (Camzyos, Bristol Myers Squibb) continues to show promising results in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a consultant cardiologist said ...
Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...
Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results